Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease

Movement Disorders

Volumn 22, Issue 10, 2007, Pages 1481-1484

  Balducci, Chiara ^a   Pierguidi, Laura ^a,b   Persichetti, Emanuele ^a   Parnetti, Lucilla ^a   Sbaragli, Michele ^a   Tassi, Carmelo ^a   Orlacchio, Aldo ^a   Calabresi, Paolo ^a,b   Beccari, Tommaso ^a   Rossi, Aroldo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

mannosidase; glucocerebrosidase; hexosaminidase; mannosidase; Parkinson's disease

Indexed keywords

ALPHA MANNOSIDASE; BETA GALACTOSIDASE; BETA MANNOSIDASE; BETA N ACETYLHEXOSAMINIDASE; LYSOSOME ENZYME;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; FEMALE; GENETIC ASSOCIATION; HUMAN; MALE; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL;

AGED; CHROMATOGRAPHY, ION EXCHANGE; FEMALE; HUMANS; HYALURONOGLUCOSAMINIDASE; MALE; MIDDLE AGED; PARKINSON DISEASE; STATISTICS, NONPARAMETRIC;

EID: 34548039499     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21399     Document Type: Article

References (15)

1. Lang AE, Lozano AM. Parkinson's disease. Second of two parts. N Engl J Med 1998;339:1130-1143.
2. Lwin A, Orvisky E, Goker-Alpan O, LaMarca ME, Sidransky E. Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Metab 2004;81:70-73.
3. Bembi B, Zambito M, Sidransky E, et al. Gaucher's disease with Parkinson's disease: clinical and pathological aspects. Neurology 2003;16:99-101.
4. Zimran A, Sorge J, Gross E, Kubitz M, West C, Beutler E. Prediction of severity of Gaucher's disease by identification of mutations at DNA level. Lancet 1989;2:349-352.
5. Kluijtmans LA, Whitehead AS. Methylenetetrahydrofolate reductase genotypes and predisposition to atherothrombotic disease; evidence that all three MTHFR C677T genotypes confer different levels of risk. Eur Heart J 2001;22:294-299.
6. Wong K, Sidranky E, Verma A, et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab 2004;82:192-207.
7. Roze E, Paschke E, Lopez N, et al. Dystonia and parkinsonism in GM1 Type 3 gangliosidosis. Mov Disord 2005;20:1366-1369.
8. Tessitore A, Martin MP, Sano R, et al. GM1-Ganglioside-mediated activation of the unfolded protein response causes neuronal death in a neurodegenerative gangliosidosis. Mol Cell 2004;15:753-766.
9. Beccari T, Mancuso F, Costanzi E, et al. β-Hexosaminidase, α-D-mannosidase, and β-mannosidase expression in serum from patients with carbohydrate-deficient glycoprotein syndrome type I. Clin Chim Acta 2000;302:125-132.
10. Leroy E, Boyer R, Auburger G, et al. The ubiquitin pathway in Parkinson's disease. Nature 1998;395:451.
11. Riise HM, Berg T, Nilssen O, Romeo G, Tollersrud OK, Ceccherini I. Genomic structure of the human lysosomal α-mannosidase gene (MANB). Genomics 1997;42:200-207.
12. Lee HJ, Khoshaghideh F, Patel S, et al. Clearance of α-synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci 2004;24:1888-1896.
13. El-Agnaf OMA, Salem SA, Paleologou KE, et al. Synuclein implicated in Parkinson's disease is present in extracellular biological fluids including human plasma. FASEB J 2003;17:1945-1947.
14. El-Agnaf OM, Salem SA, Paleologou KE, et al. Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 2006;20:419-425.
15. Tokuda T, Salem SA, Allsop D, et al. Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 2006;349:162-166.